Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting


Company News Release

Dr. Robert Leary will discuss computational methods for model evaluation; Dr. Mike Dunlavey will present simplified programming approaches of population model user interfaces.

  Mountain View, CA-June 12, 2008-Pharsight Corporation, a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver two poster presentations at the Population Approach Group in Europe (PAGE) 17th Annual Meeting in Marseille, France from June 18–20, 2008. Robert Leary, PhD, fellow, Pharsight Research and Development Group, will present work on computational methods for model evaluation. Mike Dunlavey, PhD, fellow, Pharsight Research and Development Group, will present new approaches on simplified programming of population model user interfaces.

These poster sessions will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight's two presentations are:
    • June 18: Simplified Programming of Population Model User Interfaces. Dr.
       Dunlavey will present a differential execution algorithm that allows a
       "painting" paradigm (called Dynamic Dialogs) as an alternative to
       event-based programming. This programming paradigm simplifies
       implementation of software products with complex graphical displays and
       user interface requirements.
    • June 19: Nonparametric Analogs to POSTHOC Estimates for Exploratory
       Data Analysis. Dr. Leary will present a nonparametric model evaluation
       method to complement commonly used approaches for exploratory data
       analysis of possible covariate relationships. This work builds on
       applied research presented by industry colleagues at past PAGE
       conferences and on Dr. Leary's earlier work in the area of nonlinear
       mixed effects (NLME) analysis.
"The development of advanced computational tools and next generation programming languages are integral to the continued growth of model-based drug development," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers' specific needs. Pharsight looks forward to presenting on specific elements of our vision for the future of model-based drug development, and is proud to again have such a wide presence at PAGE this year."
Additional information about PAGE can be found at

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.